Copyright Reports & Markets. All rights reserved.

Global Primary Progressive Multiple Sclerosis Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Primary Progressive Multiple Sclerosis Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by Product
      • 1.4.2 ApE
      • 1.4.3 Biotin
      • 1.4.4 GZ-402668
      • 1.4.5 Ibudilast
      • 1.4.6 Idebenone
      • 1.4.7 Laquinimod Sodium
      • 1.4.8 Others
    • 1.5 Market by End User
      • 1.5.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size
      • 2.1.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue 2014-2025
      • 2.1.2 Global Primary Progressive Multiple Sclerosis Treatment Sales 2014-2025
    • 2.2 Primary Progressive Multiple Sclerosis Treatment Growth Rate by Regions
      • 2.2.1 Global Primary Progressive Multiple Sclerosis Treatment Sales by Regions
      • 2.2.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Primary Progressive Multiple Sclerosis Treatment Sales by Manufacturers
      • 3.1.1 Primary Progressive Multiple Sclerosis Treatment Sales by Manufacturers
      • 3.1.2 Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Primary Progressive Multiple Sclerosis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Primary Progressive Multiple Sclerosis Treatment Revenue by Manufacturers
      • 3.2.1 Primary Progressive Multiple Sclerosis Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Primary Progressive Multiple Sclerosis Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Primary Progressive Multiple Sclerosis Treatment Price by Manufacturers
    • 3.4 Primary Progressive Multiple Sclerosis Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Primary Progressive Multiple Sclerosis Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Primary Progressive Multiple Sclerosis Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Primary Progressive Multiple Sclerosis Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Primary Progressive Multiple Sclerosis Treatment Sales by Product
    • 4.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue by Product
    • 4.3 Primary Progressive Multiple Sclerosis Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Primary Progressive Multiple Sclerosis Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Primary Progressive Multiple Sclerosis Treatment by Countries
      • 6.1.1 North America Primary Progressive Multiple Sclerosis Treatment Sales by Countries
      • 6.1.2 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Primary Progressive Multiple Sclerosis Treatment by Product
    • 6.3 North America Primary Progressive Multiple Sclerosis Treatment by End User

    7 Europe

    • 7.1 Europe Primary Progressive Multiple Sclerosis Treatment by Countries
      • 7.1.1 Europe Primary Progressive Multiple Sclerosis Treatment Sales by Countries
      • 7.1.2 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Primary Progressive Multiple Sclerosis Treatment by Product
    • 7.3 Europe Primary Progressive Multiple Sclerosis Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Primary Progressive Multiple Sclerosis Treatment by Countries
      • 8.1.1 Asia Pacific Primary Progressive Multiple Sclerosis Treatment Sales by Countries
      • 8.1.2 Asia Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Primary Progressive Multiple Sclerosis Treatment by Product
    • 8.3 Asia Pacific Primary Progressive Multiple Sclerosis Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Primary Progressive Multiple Sclerosis Treatment by Countries
      • 9.1.1 Central & South America Primary Progressive Multiple Sclerosis Treatment Sales by Countries
      • 9.1.2 Central & South America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Primary Progressive Multiple Sclerosis Treatment by Product
    • 9.3 Central & South America Primary Progressive Multiple Sclerosis Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment by Countries
      • 10.1.1 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment by Product
    • 10.3 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment by End User

    11 Company Profiles

    • 11.1 F. Hoffmann-La Roche Ltd.
      • 11.1.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.2 Genzyme Corporation
      • 11.2.1 Genzyme Corporation Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.2.5 Genzyme Corporation Recent Development
    • 11.3 Glialogix, Inc.
      • 11.3.1 Glialogix, Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.3.5 Glialogix, Inc. Recent Development
    • 11.4 Kyorin Pharmaceutical Co., Ltd.
      • 11.4.1 Kyorin Pharmaceutical Co., Ltd. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.4.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
    • 11.5 MedDay SA
      • 11.5.1 MedDay SA Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 MedDay SA Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 MedDay SA Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.5.5 MedDay SA Recent Development
    • 11.6 Santhera Pharmaceuticals Holding AG
      • 11.6.1 Santhera Pharmaceuticals Holding AG Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.6.5 Santhera Pharmaceuticals Holding AG Recent Development
    • 11.7 Teva Pharmaceutical Industries Ltd.
      • 11.7.1 Teva Pharmaceutical Industries Ltd. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Products Offered
      • 11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development

    12 Future Forecast

    • 12.1 Primary Progressive Multiple Sclerosis Treatment Market Forecast by Regions
      • 12.1.1 Global Primary Progressive Multiple Sclerosis Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Primary Progressive Multiple Sclerosis Treatment Market Forecast by Product
      • 12.2.1 Global Primary Progressive Multiple Sclerosis Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Primary Progressive Multiple Sclerosis Treatment Market Forecast by End User
    • 12.4 North America Primary Progressive Multiple Sclerosis Treatment Forecast
    • 12.5 Europe Primary Progressive Multiple Sclerosis Treatment Forecast
    • 12.6 Asia Pacific Primary Progressive Multiple Sclerosis Treatment Forecast
    • 12.7 Central & South America Primary Progressive Multiple Sclerosis Treatment Forecast
    • 12.8 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Primary Progressive Multiple Sclerosis Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Primary Progressive Multiple Sclerosis Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Primary Progressive Multiple Sclerosis Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Primary Progressive Multiple Sclerosis Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Primary Progressive Multiple Sclerosis Treatment in these regions.
      This research report categorizes the global Primary Progressive Multiple Sclerosis Treatment market by top players/brands, region, type and end user. This report also studies the global Primary Progressive Multiple Sclerosis Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      F. Hoffmann-La Roche Ltd.
      Genzyme Corporation
      Glialogix, Inc.
      Kyorin Pharmaceutical Co., Ltd.
      MedDay SA
      Santhera Pharmaceuticals Holding AG
      Teva Pharmaceutical Industries Ltd.

      Market size by Product
      ApE
      Biotin
      GZ-402668
      Ibudilast
      Idebenone
      Laquinimod Sodium
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Primary Progressive Multiple Sclerosis Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Primary Progressive Multiple Sclerosis Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Primary Progressive Multiple Sclerosis Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Primary Progressive Multiple Sclerosis Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Primary Progressive Multiple Sclerosis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Primary Progressive Multiple Sclerosis Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now